요오드화나트륨(123Ⅰ)

Sodium Iodide (123I)

원료 코드 M102442 국내 제품 1개 (단일제 1 · 복합제 0) DUR 성분 D001770

🌐 미국 FDA 자료(영문 라벨·부작용 보고·리콜)가 있습니다. 한국어는 AI 번역 참고용이니 원문을 함께 확인하세요. 해외 정보 보기

⚠️ DUR 안전사용 기준

  • 🤰 임부금기 1등급 (용액주사제/경구용액제)

이 성분만 든 제품 (단일제 1)

🌐 해외(미국) 정보 — 요오드화나트륨(123Ⅰ)

미국 FDA·NLM 자료 · 2026-10-03 기준

이 성분은 한국어 번역이 없습니다(검수 전 자동 번역 게시는 멈춰 두었습니다). 아래는 미국 FDA 원문입니다 — 원문 라벨(DailyMed).

미국에서 쓰이는 곳(적응증)

영어 원문 (미국 FDA 라벨)

Sodium Iodide I-131 Solution is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. Sodium Iodide I-131 is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid.

쓰면 안 되는 경우

영어 원문 (미국 FDA 라벨)

Sodium Iodide I-131 is contraindicated in: Patients with vomiting and diarrhea [see Warning and Precautions (5.7) ] . Patients with thyroid malignancies shown to have no iodide uptake, which include the majority of medullary or anaplastic carcinomas. Patients receiving concurrent anti-thyroid therapy [see Warning and Precautions (5.1) and Drug Interactions (7) ] . Pregnancy [see Warnings and Precautions (5.4) , see Use in Specific Populations (8.1) ] . Lactation [see Warnings and Precautions (5.5) ] . Patients with vomiting and diarrhea. ( 4 ) Patients with thyroid malignancies shown to have no iodide uptake. ( 4 ) Patients receiving concurrent anti-thyroid therapy. Pregnancy. ( 4 ) Lactation. ( 4 )

주요 경고·주의

영어 원문 (미국 FDA 라벨)

Radiation-induced thyroiditis may cause or worsen hyperthyroidism. Consider pre-treatment with anti-thyroid medications. ( 5.1 ) Multiple non-thyroid radiation toxicities, including hematopoietic suppression: Individualize dose and monitor for toxicity. ( 5.2 ) Fetal toxicity: May cause severe and irreversible hypothyroidism in the neonate. Verify absence of pregnancy before administering the product. ( 5.4 , 8.1 , 8.3 ) Radiation exposure to breast tissue with lactation: Sodium iodide I 131 concentrates in the breast of lactating women. Discontinue lactation 6 weeks prior to therapy. ( 5.5 , 8.2 ) 5.1 Radiation-induced Thyroiditis Sodium iodide I 131 may cause thyroiditis with release of thyroid hormone, which may aggravate hyperthyroidism and thyrotoxic cardiac disease [see Adverse Reactions (6) ] . When treating hyperthyroidism, consider pre-treatment anti-thyroid medication to help deplete the thyroid hormone. Discontinue the anti-thyroid therapy three days before administration of sodium iodide I 131 [see Drug Interactions (7) ] . Consider a beta-blocker pre or post-treatment to minimize the risk of hyperthyroidism and thyroid storm. The thyroiditis may cause gland enlargement resulting in tenderness and swelling of the neck, pain on swallowing, sore throat, and cough; which may occur approximately the third day after sodium iodide I 131 administration. Consider management with pain-reliever or anti-inflammatory medications. 5.2 Radiation-induced Toxicities Sodium …

임신·특수 환자

영어 원문 (미국 FDA 라벨)

8.1 Pregnancy Risk Summary Sodium Iodide I-131 is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible [see Warnings and Precautions (5.4) ] . Data from the published literature describe thyroid abnormalities after fetal exposure; including agenesis of the thyroid and hypothyroidism (see Data ). No animal reproductive studies have been conducted. Clinical Considerations . Fetal/ Neonatal Adverse Reactions A fetus exposed to sodium iodide I 131 can develop neonatal hypothyroidism. Delay in diagnosis of neonatal hypothyroidism after exposure to sodium iodide I 131 in utero can result in severe sequelae such as …

미국 제품명 HICON

미국 부작용 보고(FAERS)에 많이 나온 증상

미국 FDA에 접수된 이 성분 관련 보고 1,122건 가운데 많이 적힌 증상입니다. 보고 수는 약 때문이라는 증거가 아니며, 많이 쓰는 약일수록 많아집니다. 증상 이름의 한국어는 AI 번역(참고용)이라 영어 원어를 함께 적었습니다.

  1. 1 갑상선 기능 저하증hypothyroidism402
  2. 2 ENDOCRINE OPHTHALMOPATHY45
  3. 3 HYPERTHYROIDISM31
  4. 4 치료 실패treatment failure30
  5. 5 ABORTION SPONTANEOUS26
  6. 6 오심nausea26
  7. 7 약효 없음drug ineffective25
  8. 8 ACUTE MYELOID LEUKAEMIA24
  9. 9 DACRYOSTENOSIS ACQUIRED24
  10. 10 MATERNAL EXPOSURE BEFORE PREGNANCY22
  11. 11 PARATHYROID TUMOUR BENIGN22
  12. 12 LACRIMATION INCREASED21

미국 리콜 기록

FDA 리콜(회수) 기록 3건 중 최근 3건 — 특정 회사·제조번호 제품의 회수로, 국내 제품과는 관계없을 수 있습니다.

  • 2026.04.01 · 3등급(경미) · Radnostix Failed Tablet/Capsule Specifications
  • 2026.03.11 · 2등급 · Radnostix Presence of Particulate Matter: Due to production issues
  • 2016.04.13 · 3등급(경미) · Jubilant Draximage Inc Labeling: Label Error on Declared Strength

출처: 미국 FDA openFDA(라벨·FAERS·리콜), 미국 국립의학도서관 RxNorm · DailyMed 원문 라벨. 한국어는 오픈드럭 서버 AI(gemma)가 자동 번역한 참고용(사람 검수 전)으로 오역이 있을 수 있으니 반드시 원문을 확인하세요.

같은 성분의 다른 원료(염·형태)

요오드화나트륨(123I) 1